Inhibikase Therapeutics (Inhibikase Therapeutics) EV-to-EBIT : -0.11 (As of May. 25, 2024)

Inhibikase Therapeutics EV-to-EBIT Chart

Inhibikase Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															0.27	0.08	0.46	0.26	-0.22

Competitive Comparison of Inhibikase Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Inhibikase Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's EV-to-EBIT falls into.

Inhibikase Therapeutics EV-to-EBIT Calculation

Inhibikase Therapeutics's EV-to-EBIT for today is calculated as:

Inhibikase Therapeutics's current Enterprise Value is $2.31 Mil.
Inhibikase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics  (NAS:IKT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Inhibikase Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Inhibikase Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $4.45 Mil.
Inhibikase Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description